Form 4: CEO Daniel Virnich Acquires TOI Shares
Insider Transaction Report
The Oncology Institute CEO Daniel Virnich acquired 6,464 shares of common stock through vested RSU awards.
Summary
- Daniel Virnich, Chief Executive Officer of The Oncology Institute, Inc. (TOI), acquired 6,464 shares of common stock.
- The transaction occurred on November 17, 2025.
- The shares were acquired as Restricted Stock Unit (RSU) awards that fully vested upon grant, net of withholding tax obligations, with a transaction price of $0.00 per share.
- Following this transaction, Daniel Virnich beneficially owns 1,799,984 shares of The Oncology Institute, Inc. common stock.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a routine compensation event, the increase in insider ownership, even if compensation-related, generally aligns management's interests with shareholders and does not indicate any negative developments.
Positives
- The acquisition of shares by the Chief Executive Officer increases insider ownership, which can align management's interests with those of shareholders.
- The vesting of RSUs represents a planned compensation event, indicating the company is fulfilling its executive compensation structure.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.
Industry Context
Insider transactions, such as the vesting and acquisition of shares through RSU awards, are common practices in executive compensation across various industries. While this specific transaction is routine, increased insider ownership can sometimes be viewed positively by the market as it suggests management's confidence in the company's future.
Stakeholder Impact
- Shareholders: The increase in the CEO's beneficial ownership may be viewed positively as it aligns management's interests with those of other shareholders.
Key Dates
| Date | Description |
|---|---|
| 11/17/2025 | Date of transaction where Daniel Virnich acquired 6,464 shares of common stock. |
| 11/19/2025 | Date the Form 4 was signed by Mark Hueppelsheuser, Attorney-in-Fact for Daniel Virnich. |
Keywords
The Oncology Institute, TOI, Daniel Virnich, CEO, Insider Trading, Form 4, Stock Acquisition, RSU, Restricted Stock Units, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.